[go: up one dir, main page]

SG10202102251YA - Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 - Google Patents

Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Info

Publication number
SG10202102251YA
SG10202102251YA SG10202102251YA SG10202102251YA SG10202102251YA SG 10202102251Y A SG10202102251Y A SG 10202102251YA SG 10202102251Y A SG10202102251Y A SG 10202102251YA SG 10202102251Y A SG10202102251Y A SG 10202102251YA SG 10202102251Y A SG10202102251Y A SG 10202102251YA
Authority
SG
Singapore
Prior art keywords
ccr4
hla
egfr
proteins binding
binding nkg2d
Prior art date
Application number
SG10202102251YA
Inventor
Gregory Chang
Ann Cheung
Jinyan Du
Asya Grinberg
William Haney
Dhruv Sethi
Nicolai Wagtmann
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG10202102251YA publication Critical patent/SG10202102251YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202102251YA 2017-08-16 2018-08-16 Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 SG10202102251YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762546300P 2017-08-16 2017-08-16
US201762546297P 2017-08-16 2017-08-16
US201762552152P 2017-08-30 2017-08-30
US201762555114P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
SG10202102251YA true SG10202102251YA (en) 2021-04-29

Family

ID=65362495

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102251YA SG10202102251YA (en) 2017-08-16 2018-08-16 Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
SG11201913969SA SG11201913969SA (en) 2017-08-16 2018-08-16 Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201913969SA SG11201913969SA (en) 2017-08-16 2018-08-16 Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Country Status (12)

Country Link
US (2) US20200216544A1 (en)
EP (2) EP3668893A4 (en)
JP (2) JP2020531438A (en)
KR (2) KR20210029298A (en)
CN (2) CN113004391A (en)
AU (2) AU2018318698A1 (en)
BR (1) BR112020003050A2 (en)
CA (3) CA3073117A1 (en)
IL (2) IL272553A (en)
MX (2) MX2020001805A (en)
SG (2) SG10202102251YA (en)
WO (1) WO2019035939A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multispecific binding proteins for activation of NATURAL KILLER CELLS and their medical uses for cancer treatment
FI3582806T3 (en) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc HER2, NKG2D AND CD16 BINDING PROTEINS
KR20200118824A (en) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. Combination therapy for cancer involving multi-specific binding proteins that activate natural killer cells
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
JP7353576B2 (en) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Multispecific binding proteins that bind to CD33, NKG2D, and CD16, and methods of use thereof
SG11202011139YA (en) * 2018-05-16 2020-12-30 Dragonfly Therapeutics Inc Protein binding nkg2d, cd16 and a fibroblast activation protein
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
MA53284A (en) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEINS
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
WO2021209049A1 (en) * 2020-04-16 2021-10-21 南通壹宸生物医药科技有限公司 Pd-1 mutant polypeptide, and preparation therefor and use thereof
AR122018A1 (en) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc NKG2D, CD16 AND CLEC12A BINDING PROTEINS
IL300249A (en) * 2020-08-05 2023-03-01 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and egfr
CN112029001B (en) * 2020-09-02 2022-09-06 南京北恒生物科技有限公司 Chimeric antigen receptors targeting NK activating receptors
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN115246886A (en) * 2021-04-27 2022-10-28 丹生医药技术(上海)有限公司 anti-EGFR/VEGF (epidermal growth factor receptor/vascular endothelial growth factor) bifunctional fusion protein and application thereof
US20240352132A1 (en) * 2021-07-14 2024-10-24 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
CN116284430A (en) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 Tumor-targeted IL15 fusion protein and its application
WO2023043861A2 (en) * 2021-09-16 2023-03-23 Biohaven Therapeutics Ltd. Conjugated antibodies for treating diseases
US20230250176A1 (en) * 2022-02-09 2023-08-10 Dragonfly Therapeutics, Inc. Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
JP2025528087A (en) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ，リミテッド Multispecific antibodies targeting dimerizable tumor antigens and immunostimulatory antigens
WO2024213097A1 (en) * 2023-04-14 2024-10-17 山东先声生物制药有限公司 Multispecific antibody targeting human cd16 and tumor antigen
CN121443647A (en) * 2023-07-07 2026-01-30 四川科伦博泰生物医药股份有限公司 EGFR/c-MET bispecific binding proteins and uses thereof
WO2025011471A1 (en) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Egfr/c-met bispecific binding protein and use thereof
TW202517675A (en) * 2023-07-19 2025-05-01 大陸商映恩生物製藥（蘇州）有限公司 A bispecific antibody, a drug conjugate thereof and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299137A1 (en) * 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PT2222706E (en) 2007-12-14 2014-07-28 Novo Nordisk As Antibodies against human nkg2d and uses thereof
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
UY32808A (en) * 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2817964C (en) * 2010-11-17 2018-06-12 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN107903325B (en) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014079000A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
HRP20191470T1 (en) * 2013-03-15 2020-01-10 Xencor, Inc. Heterodimeric proteins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
MX2016008667A (en) * 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof.
AP2016009586A0 (en) * 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
SG11201701385WA (en) * 2014-08-28 2017-03-30 Academisch Ziekenhuis Leiden Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
WO2016070959A1 (en) * 2014-11-03 2016-05-12 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
AU2015373910B2 (en) * 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
TW201627322A (en) * 2015-01-26 2016-08-01 宏觀基因股份有限公司 Anti-DR5 antibodies and molecules comprising DR5-binding domains thereof
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
US20180147257A1 (en) * 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins, compositions comprising same and uses thereof
JP6991979B2 (en) * 2016-02-05 2022-03-04 オリオニス バイオサイエンシズ ビーブイ CD8 binding substance
JP7536424B2 (en) * 2016-02-26 2024-08-20 イミュネクサス・セラピューティクス・リミテッド Multispecific molecules

Also Published As

Publication number Publication date
CN113004391A (en) 2021-06-22
IL281305A (en) 2021-04-29
WO2019035939A1 (en) 2019-02-21
KR20200037388A (en) 2020-04-08
EP3882270A2 (en) 2021-09-22
CA3112990A1 (en) 2019-02-21
IL272553A (en) 2020-03-31
EP3668893A1 (en) 2020-06-24
US20210261668A1 (en) 2021-08-26
SG11201913969SA (en) 2020-01-30
CA3073117A1 (en) 2019-02-21
CN111065649A (en) 2020-04-24
CA3176049A1 (en) 2019-02-21
MX2020001805A (en) 2020-07-13
JP2020531438A (en) 2020-11-05
AU2018318698A1 (en) 2020-02-20
US20200216544A1 (en) 2020-07-09
EP3668893A4 (en) 2021-08-04
KR20210029298A (en) 2021-03-15
AU2021201451A1 (en) 2021-03-25
JP2021098732A (en) 2021-07-01
EP3882270A3 (en) 2021-12-01
MX2021002969A (en) 2021-05-12
BR112020003050A2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
IL272553A (en) Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
IL268567A (en) Proteins binding bcma, nkg2d and cd16
IL277398A (en) Pd-l1 binding affimers, and uses related thereto
IL268790A (en) Proteins binding cd33, nkg2d and cd16
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
IL270794A (en) A protein binding nkg2d, cd16 and ror1 or ror2
IL272374A (en) NKG2D, CD16, and FLT3 binding proteins
IL268768A (en) Proteins binding gd2, nkg2d and cd16
EP3681532A4 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
SG11202100883SA (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
IL268574A (en) Proteins binding psma, nkg2d and cd16
IL268766A (en) Proteins binding cd123, nkg2d and cd16
SG11202111012QA (en) Trispecific binding proteins, methods, and uses thereof
IL277519A (en) Antagonistic pd-1, pd-l1 and lag-3 binding proteins
IL273202A (en) Binding proteins to the human thrombin receptor, par4
HK40014030A (en) Proteins binding bcma, nkg2d and cd16
HK40030226A (en) Proteins binding nkg2d, cd16 and flt3
HK40014039A (en) Proteins binding cd33, nkg2d and cd16
ZA201905273B (en) Proteins binding psma, nkg2d and cd16
HK40019734A (en) Proteins binding cd123, nkg2d and cd16
HK40044284A (en) Pd-l1 binding affimers, and uses related thereto
HK40019178A (en) Proteins binding psma, nkg2d and cd16
HK40027628A (en) A protein binding nkg2d, cd16 and ror1 or ror2
HK40055054A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
HK40032894A (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)